Search
Nektar Therapeutics
NKTRAdd to Watchlist
71.040USD
+6.650+10.33%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.40BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+10.33%
5 Days
+11.61%
1 Month
+19.78%
6 Months
+63.61%
Year to Date
+68.02%
1 Year
+186.91%
Key Figures
65.030Open
71.200High
1.12MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
5.70%Turnover Ratio
64.390Prev. Close
64.970Low
52.13MTurnover
LossP/E Static
16.41P/B
0.00%Div Yield TTM
-31.01%ROA
109.00052wk High
0.78Volume Ratio
-118.96MNet Profit
19.65MShares
-7.9223EPS TTM
1.17Beta
-53.60%ROE
7.99052wk Low
9.68%Amplitude
100.00%Gross Margin
1.40BMarket Cap
2.10Reward/Risk
4.08%Risk Rate
TradingKey Stock Score of Nektar Therapeutics
Currency: USD Updated: 2026-07-02Key Insights
Nektar Therapeutics's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 77 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 153.25.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Nektar Therapeutics's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Nektar Therapeutics Highlights
StrengthsRisks
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Growing
The company is in a growing phase, with the latest annual income totaling USD 55.23M.
Undervalued
The company’s latest PE is -8.97, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 20.71M shares, increasing 6.00% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 16.51K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.16.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
153.250
Target Price
+138.00%
Upside Space
Nektar Therapeutics News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Nektar Therapeutics Info
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Ticker SymbolNKTR
CompanyNektar Therapeutics
CEORobin (Howard W)
Websitehttps://www.nektar.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Nektar Therapeutics (NKTR)?
The current price of Nektar Therapeutics (NKTR) is 71.04.
What is the symbol of Nektar Therapeutics?
The ticker symbol of Nektar Therapeutics is NKTR.
What is the 52-week high of Nektar Therapeutics?
The 52-week high of Nektar Therapeutics is 109.00.
What is the 52-week low of Nektar Therapeutics?
The 52-week low of Nektar Therapeutics is 7.99.
What is the market capitalization of Nektar Therapeutics?
The market capitalization of Nektar Therapeutics is 1.40B.
Is Nektar Therapeutics (NKTR) currently rated as Buy, Hold, or Sell?
According to analysts, Nektar Therapeutics (NKTR) has an overall rating of Buy, with a price target of 153.25.
What is the Earnings Per Share (EPS TTM) of Nektar Therapeutics (NKTR)?
The Earnings Per Share (EPS TTM) of Nektar Therapeutics (NKTR) is -9.73.